Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00467-4/fulltext?dgcid=hubspot_update_feature_updatealerts_eclinm&utm_campaign=update-eclinm&utm_medium=email&_hsmi=285633353&_hsenc=p2ANqtz-90qooVYN2s1OYpJPI_hA3HV4Ujh3IP66GzcQp48vQj-BQDudVurj1ypqYM6vkDa7HAib3Gymj80WiVJRtGc5YE8I-CVQ&utm_content=285625883&utm_source=hs_email